当前位置： SCI文献检索 > Clinical Genitourinary Cancer期刊下所有文献 > Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era.

Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era.

Abstract：

BACKGROUND:The objective of this study was to determine the outcomes of young adults with kidney cancer treated during the targeted therapy era and evaluate the impact of young age on survival. MATERIALS AND METHODS:We reviewed the records from 445 patients younger than 55 years with kidney cancer at a single institution from 2006 to 2017. Overall survival (OS) and recurrence-free survival were estimated with the Kaplan-Meier method and log-rank test. Cox proportional hazards regression was used to determine the impact of clinical and pathologic variables on all-cause mortality. RESULTS:Overall, 104 (23%) patients 40 years or younger were compared with 341 (77%) patients who were 41 to 55 years old. Younger patients presented with more advanced stages of the disease, including metastasis at diagnosis, positive lymph nodes, venous tumor thrombus and had more non-clear cell tumors (54% vs. 30%; P < .001). Young adults had significantly worse OS at 2 and 5 years (67% vs. 82% and 53% vs. 69%, respectively). Younger patients with metastatic disease received targeted agents less often compared with the older group (64% vs. 75%). There was no difference in recurrence-free survival across patients with localized disease. Independent prognostic factors associated with increased mortality were metastasis at diagnosis, pT2 or greater, and age younger than 40 years (hazard ratio, 1.65; 95% confidence interval, 1.0-2.6; P = .03). CONCLUSION:Patients younger than 40 years with kidney tumors treated during the targeted therapy era have worse OS compared with older adults. Young age is an independent predictor of mortality.

journal_name

Clin Genitourin Cancer

journal_title

Clinical genitourinary cancer

authors

Sierra PS,Cordeiro MD,Albuquerque EV,Bastos DA,Bonadio RC,Sarkis AS,Cavalcante A,Pontes J Jr,Coelho RF,Nahas WC

doi

10.1016/j.clgc.2019.09.012

subject

Has Abstract

pub_date

2020-04-01 00:00:00

pages

e134-e144

issue

2

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(19)30281-2

journal_volume

18

pub_type

杂志文章

相关文献

Clinical Genitourinary Cancer文献大全
  • Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands.

    abstract：BACKGROUND:The purpose of this study was to determine generic, cancer-specific, and prostate cancer-specific health-related quality of life (HRQoL), pain and changes over time in patients with metastatic castration-resistant prostate cancer (mCRPC) in daily practice. PATIENTS AND METHODS:PRO-CAPRI is an observational,...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.11.015

    authors： Kuppen MCP,Westgeest HM,van den Eertwegh AJM,Coenen JLLM,van Moorselaar RJA,van den Berg P,Geenen MM,Mehra N,Hendriks MP,Lampe MI,van de Luijtgaarden ACM,Peters FPJ,Roeleveld TA,Smilde TJ,de Wit R,van Oort IM,Gerritsen WR

    更新日期：2020-06-01 00:00:00

  • Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.

    abstract：BACKGROUND:Results from large randomized controlled trials combining docetaxel, abiraterone, celecoxib, or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer have emerged. However, in our knowledge, few data are available in patients older than 70 years. Therefore, we undertook...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clgc.2019.05.001

    authors： Landre T,Guetz GD,Chouahnia K,Fossey-Diaz V,Taleb C,Culine S

    更新日期：2019-08-01 00:00:00

  • Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma and End-stage Renal Disease at 2 Centers.

    abstract：INTRODUCTION:There is scarce information regarding nivolumab treatment for metastatic renal cell carcinoma (mRCC) in patients with end-stage renal disease (ESRD). This study investigated the safety and efficacy of nivolumab in patients with mRCC and ESRD. MATERIALS AND METHODS:This 2-center retrospective study evaluat...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2019.04.004

    authors： Tachibana H,Kondo T,Ishihara H,Takagi T,Tanabe K

    更新日期：2019-08-01 00:00:00

  • Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration.

    abstract：PURPOSE:To determine the therapeutic value of lymph node dissection (LND) during cytoreductive nephrectomy (CN) and assess predictors of cancer-specific survival (CSS) in metastatic renal-cell carcinoma. PATIENTS AND METHODS:We identified 293 consecutive patients treated with CN at 4 academic institutions from March 2...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2017.10.004

    authors： Chipollini J,Abel EJ,Peyton CC,Boulware DC,Karam JA,Margulis V,Master VA,Zargar-Shoshtari K,Matin SF,Sexton WJ,Raman JD,Wood CG,Spiess PE

    更新日期：2018-04-01 00:00:00

  • Histopathologic Characteristics of Upper Tract Urothelial Carcinoma With an Emphasis on Their Effect on Cancer Survival: A Single-Institute Experience With 305 Patients With Long-Term Follow-Up.

    abstract：INTRODUCTION:Tumor stage and grade represent the best established predictors for the prognosis of upper tract urothelial carcinoma (UTUC). However, controversies still exist regarding the role of tumor necrosis, location, and multifocality in the prognosis of UTUC. We share our experience with 305 patients, reporting o...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.04.017

    authors： Elawdy MM,Taha DE,Elbaset MA,Abouelkheir RT,Osman Y

    更新日期：2016-12-01 00:00:00

  • Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.

    abstract：BACKGROUND:In the phase III axitinib second-line (AXIS) trial, axitinib significantly prolonged progression-free survival (PFS) versus sorafenib in patients with previously treated metastatic renal cell carcinoma (mRCC). Analyses of associations between germline single-nucleotide polymorphisms (SNPs) and outcomes are r...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clgc.2015.02.007

    authors： Escudier B,Rini BI,Motzer RJ,Tarazi J,Kim S,Huang X,Rosbrook B,English PA,Loomis AK,Williams JA

    更新日期：2015-08-01 00:00:00

  • Primary extraosseous ewing sarcoma of the kidney with level III inferior vena cava thrombus.

    abstract：:Ewing sarcoma typically presents as a skeletal-based tumor, with rare instances of peripheral primitive neuroectodermal tumor (PNET) arising in the soft tissues. Few examples of organ-based PNETs have been previously described in the literature. These tumors are exceedingly rare as a primary renal neoplasm. To our kno...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2009.n.032

    authors： Fergany AF,Dhar N,Budd GT,Skacel M,Garcia JA

    更新日期：2009-10-01 00:00:00

  • A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings.

    abstract：BACKGROUND:The role of chemotherapy in nodal metastases from penile squamous cell carcinoma is not defined. We evaluated the efficacy of a combination of T-PF (a taxane, cisplatin, and 5-fluorouracil) in neoadjuvant and adjuvant settings. PATIENTS AND METHODS:Since June of 2004, T-PF was administered to stage N2 to 3 ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.07.009

    authors： Nicolai N,Sangalli LM,Necchi A,Giannatempo P,Paganoni AM,Colecchia M,Piva L,Catanzaro MA,Biasoni D,Stagni S,Torelli T,Raggi D,Faré E,Pizzocaro G,Salvioni R

    更新日期：2016-08-01 00:00:00

  • Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases.

    abstract：BACKGROUND:Modern radiation techniques have led to significant improvements in intracranial disease control and overall survival (OS) for metastatic renal-cell carcinoma (mRCC) patients diagnosed with brain metastases (BM). The impact of systemic therapy in patients developing mRCC BM remains undercharacterized. PATIE...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.10.024

    authors： Parmar A,Soliman H,Sahgal A,Bjarnason GA

    更新日期：2020-06-01 00:00:00

  • Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice.

    abstract：BACKGROUND:Non-muscle-invasive bladder cancer (NMIBC) can be treated using transurethral resection (TUR), but high incidence of intravesical recurrence remains a clinical challenge. Single immediate postoperative instillation of chemotherapy (IPIOC) is controversial for NMIBC patients with intermediate recurrence risk....

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.05.028

    authors： Murakami K,Hamada A,Teramoto Y,Matsumoto K,Kita Y,Saito R,Yamasaki T,Matsui Y,Inoue T,Ogawa O,Kobayashi T

    更新日期：2019-10-01 00:00:00

  • Comparison of Laparoscopic and Robot-assisted Radical Cystectomy for Bladder Cancer: Perioperative and Oncologic Outcomes.

    abstract：BACKGROUND:The purpose of this study was to compare perioperative and oncologic outcomes between laparoscopic radical cystectomy (LRC) and robot-assisted radical cystectomy (RARC) for bladder cancer (BCa). MATERIALS AND METHODS:Patients who underwent LRC or RARC with curative intent for BCa between January 2011 and De...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.06.007

    authors： Su S,Gu L,Ma X,Li H,Wang B,Shi T,Zhang X

    更新日期：2019-10-01 00:00:00

  • Human immunodeficiency virus--associated renal cell carcinoma: a transatlantic case series.

    abstract：OBJECTIVE:The spectrum of diseases associated with human immunodeficiency virus (HIV) infection has changed dramatically following the introduction of highly active antiretroviral therapy (HAART). Non-AIDS-defining cancers, including renal cell carcinoma (RCC), are being recognized increasingly in this population. Our ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2008.n.013

    authors： Gaughan EM,Dezube BJ,Aboulafia D,Bower M,Stebbing J,Powles T,Pantanowitz L

    更新日期：2008-09-01 00:00:00

  • A phase II study of depsipeptide in refractory metastatic renal cell cancer.

    abstract：BACKGROUND:Therapeutic options for renal cell cancer are inadequate. Depsipeptide is a histone deacetylase inhibitor with promising preclinical and early clinical activity. PATIENTS AND METHODS:Patients with refractory renal cell cancer with normal organ function and no history of significant cardiovascular disease we...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/CGC.2006.n.018

    authors： Stadler WM,Margolin K,Ferber S,McCulloch W,Thompson JA

    更新日期：2006-06-01 00:00:00

  • Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.

    abstract：INTRODUCTION:The objective of this study was to determine the effectiveness and safety of pazopanib in patients with intermediate-risk advanced/metastatic renal cell carcinoma in the PRINCIPAL study (NCT01649778). PATIENTS AND METHODS:Patients had clear-cell advanced/metastatic renal cell carcinoma and met intermediat...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.01.018

    authors： Procopio G,Bamias A,Schmidinger M,Hawkins R,Sánchez AR,Estevez SV,Srihari N,Kalofonos H,Bono P,Pisal CB,Hirschberg Y,Dezzani L,Ahmad Q,Rodriguez CS,Jonasch E

    更新日期：2019-06-01 00:00:00

  • Combined Angiogenesis and Proliferation Markers' Expressions as Long-Term Prognostic Factors in Renal Cell Cancer.

    abstract：OBJECTIVES:The aim of this study was to evaluate the expression of MIB-1, BCL-2, VEGFR3, and CD31 and their associations with long-term survival in patients with renal cell cancer (RCC). PATIENTS AND METHODS:This study consisted of 224 RCC patients who underwent radical nephrectomy from 1985 to 1995. Follow-up continu...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.12.014

    authors： Virman JP,Bono P,Luukkaala TH,Sunela KL,Kujala PM,Kellokumpu-Lehtinen PL

    更新日期：2016-08-01 00:00:00

  • Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.

    abstract：:Metastatic renal cell carcinoma has long been recognized as an aggressive, therapy-refractory epithelial cancer. Two decades of clinical experience with the biologic response modifiers, such as interferon and interleukin-2, have produced little in the way of clinically meaningful benefit for patients, with the notable...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cgc.2006.s.003

    authors： Dreicer R

    更新日期：2006-12-01 00:00:00

  • Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.

    abstract：BACKGROUND:Cisplatin-based neoadjuvant chemotherapy (NAC) before cystectomy improves survival in muscle-invasive urothelial bladder cancer (MIBC). The use of NAC before chemoradiation (CRT) has been limited, as these patients are often elderly, frail, and ineligible for cisplatin. However, the role of NAC in fit, cispl...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.09.021

    authors： Jiang DM,Jiang H,Chung PWM,Zlotta AR,Fleshner NE,Bristow RG,Berlin A,Kulkarni GS,Alimohamed NS,Lo G,Sridhar SS

    更新日期：2019-02-01 00:00:00

  • Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.

    abstract：BACKGROUND:The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guérin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS:We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic c...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2019.10.021

    authors： D'Andrea D,Soria F,Abufaraj M,Pones M,Gontero P,Machado AT,Waksman R,Enikeev DV,Glybochko PV,Adonias SP,Nahas WC,Shariat SF,Chade DC

    更新日期：2020-02-01 00:00:00

  • A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.

    abstract：BACKGROUND:Tamoxifen (TAM) has been shown to be active against the bicalutamide-induced breast events (BEs) gynecomastia, and breast pain in patients with prostate cancer (PC). Optimal doses and schedules are not yet established. Debate still exists about whether prophylaxis with TAM is more effective than treatment of...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clgc.2012.03.002

    authors： Serretta V,Altieri V,Morgia G,Nicolosi F,De Grande G,Mazza R,Melloni D,Allegro R,Ferraù F,Gebbia V

    更新日期：2012-09-01 00:00:00

  • Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.

    abstract：BACKGROUND:Cabozantinib showed efficacy and manageable toxicity in patients with metastatic renal cell carcinoma (mRCC). In this study we aimed to describe the safety and to collect evidence on the potential efficacy of cabozantinib in mRCC patients with brain metastases (BM) in a real-world experience. MATERIALS AND ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.05.002

    authors： Peverelli G,Raimondi A,Ratta R,Verzoni E,Bregni M,Cortesi E,Cartenì G,Fornarini G,Facchini G,Buti S,Galli L,Tucci M,Prisciandaro M,Procopio G

    更新日期：2019-08-01 00:00:00

  • Prognostic Value of Body Mass Index According to Histologic Subtype in Nonmetastatic Renal Cell Carcinoma: A Large Cohort Analysis.

    abstract：OBJECTIVE:The objective of our study was to assess the prognostic value of body mass index (BMI) according to histologic subtype in nonmetastatic renal cell carcinoma (RCC), based on a large multicenter experience. METHODS:A total of 2769 patients with nonmetastatic RCC at the time of surgery were enrolled from 5 Kore...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2015.04.012

    authors： Lee WK,Hong SK,Lee S,Kwak C,Oh JJ,Jeong CW,Kim YJ,Kang SH,Hong SH,Byun SS

    更新日期：2015-10-01 00:00:00

  • Evaluation of Gleason Grade Group 5 in a Contemporary Prostate Cancer Grading System and Literature Review.

    abstract：INTRODUCTION:The aim of this study was to validate contemporary grading systems, in particular, the Gleason grade group (GGG) 5. PATIENTS AND METHODS:We retrospectively reviewed the clinicopathologic data of 176 patients who underwent radical prostatectomy and whose pathologic results were GGG 4 or 5. The endpoints we...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2020.08.001

    authors： Kamitani R,Matsumoto K,Kosaka T,Takeda T,Hashiguchi A,Tanaka N,Morita S,Mizuno R,Shinojima T,Asanuma H,Oya M

    更新日期：2020-08-07 00:00:00

  • Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors.

    abstract：BACKGROUND:Salvage treatment with either conventional-dose chemotherapy (CDCT) or high-dose chemotherapy with autologous stem cell transplantation (HDCT) offers curative potential for patients with relapsed or refractory germ cell tumor (GCT). However, the optimal initial salvage strategy remains controversial, and the...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.03.015

    authors： Narayan V,Gunnarsson O,Hwang WT,Squillante CM,Nathanson KL,Stadtmauer EA,Vaughn DJ

    更新日期：2016-12-01 00:00:00

  • Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma.

    abstract：INTRODUCTION:The introduction of active new agents, such as small molecules and checkpoint inhibitors, for the treatment of metastatic renal-cell cancer (mRCC) is associated with a relevant increase in costs, and it is therefore important to strike a balance between the costs of treatment and the added value represente...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.02.006

    authors： Giuliani J,Bonetti A

    更新日期：2018-06-01 00:00:00

  • The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.

    abstract：BACKGROUND:Abiraterone and enzalutamide are 2 novel androgen receptor (AR)-targeting therapies that improve survival in patients with metastatic castration-resistant prostate cancer. The factors that predict abiraterone and enzalutamide response are lacking. The objective of the present study was to determine whether t...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.03.021

    authors： Hung J,Taylor AR,Divine GW,Hafron JM,Hwang C

    更新日期：2016-10-01 00:00:00

  • Clinical Significance of Subclassification of Papillary Renal Cell Carcinoma: Comparison of Clinicopathologic Parameters and Oncologic Outcomes Between Papillary Histologic Subtypes 1 and 2 Using the Korean Renal Cell Carcinoma Database.

    abstract：INTRODUCTION:The aims of the present study were to compare the clinicopathologic characteristics between type 1 and type 2 papillary renal cell carcinoma (pRCC) and to evaluate the effect of the subclassification of pRCC on the oncologic outcomes after surgery. MATERIALS AND METHODS:The records of 274 patients with pR...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.07.020

    authors： Ha YS,Chung JW,Choi SH,Lee JN,Kim HT,Kim TH,Chung SK,Byun SS,Hwang EC,Kang SH,Hong SH,Chung J,Kwak C,Kim YJ,Kwon TG,Korean Renal Cell Carcinoma Study Group.

    更新日期：2017-04-01 00:00:00

  • Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.

    abstract：INTRODUCTION:In the first-line (1L) setting, pazopanib (PAZ) has been recommended by the National Comprehensive Cancer Network for the treatment of advanced renal cell carcinoma (aRCC). In 2018, immuno-oncology (IO) therapy became a commonly used 1L treatment option for aRCC. We report the real-world clinical outcomes ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2019.10.010

    authors： Cao X,Tang D,Ratto B,Poole A,Ravichandran S,Jin L,Gao W,Swallow E,Vogelzang NJ

    更新日期：2020-02-01 00:00:00

  • Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.

    abstract：BACKGROUND:Venous thromboembolic events (VTEs) frequently occur in cancer patients. Risk assessment models (RAMs) for cancer-associated thrombosis have been proposed. However, advanced urinary tract cancer (aUTC) was not adequately represented in these models. We studied the incidence of VTEs, the risk factors, and the...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.12.021

    authors： Bamias A,Tzannis K,Dimitriadis I,Tsironis G,Papatheorodidi AM,Tsiara A,Fragkoulis C,Xirokosta A,Barbarousi D,Papadopoulos G,Zakopoulou R,Varkarakis I,Mitsogiannis I,Adamakis I,Alamanis C,Stravodimos K,Papatsoris AG,Dell

    更新日期：2020-08-01 00:00:00

  • Global Quality of Life After Curative Treatment for Prostate Cancer: What Matters? A Study Among Members of the Norwegian Prostate Cancer Patient Association.

    abstract：INTRODUCTION:The purpose of this study was to identify factors that are associated with quality of life (QoL) in relapse-free patients after radical prostatectomy or high-dose radiotherapy with or without hormone treatment. PATIENTS AND METHODS:A cross-sectional postal survey among members of the Norwegian Prostate Ca...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.07.004

    authors： Fosså SD,Dahl AA

    更新日期：2015-12-01 00:00:00

  • Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.

    abstract：:The use of sunitinib in dialysis patients is poorly described but is of clinical importance. We report 2 cases of patients receiving sunitinib for metastatic renal cell carcinoma while undergoing dialysis. The first patient is undergoing hemodialysis and, though responding to sunitinib, is having significant fatigue a...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2009.n.035

    authors： Vickers MM,Heng DY,Hemmelgarn B,Eigl BJ

    更新日期：2009-10-01 00:00:00